Investigations into the mechanisms of hyperkalemia following renal transplantation

Ralph A Defronzo, M. Goldberg, C. R. Cooke, C. Barker, R. A. Grossman, Z. S. Agus

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Hyperkalemia was observed in 23 of 75 patients in the first three months following renal transplantation. The hyperkalemia was unrelated to rejection, renal failure, oliguria, or acidosis. Six patients (four with hyperkalemia and two with normal serum potassium) were studied to evaluate the role of the renin angiotensin aldosterone system and/or impairment of renal tubular potassium handling in this syndrome. Following equilibration on a normal dietary intake, patients were placed on a low sodium diet and were given furosemide. All patients achieved sodium and potassium balance during both periods, but at the expense of significant hyperkalemia (5.3 to 5.7 mEq/liter) in the four patients with preexisting hyperkalemia. Plasma aldosterone concentration and urinary aldosterone excretion rates in the hyperkalemic patients were 8.4 ± 0.6 ng/dl and 2.8 ± 1.1 μg/day, respectively, on a control diet, and they rose appropriately to 15.4 ± 1.9 ng/dl and 20.3 ± 1.4 μg/day with sodium restriction. Subsequent administration of exogenous mineralocorticoid, 9 α fluorohydrocortisone (Florinef), 1 mg/day, while the sodium intake was high, failed to increase urinary potassium excretion. Neither furosemide nor acetazolamide plus sodium bicarbonate administration produced a consistent increase in potassium excretion despite a significant natriuresis. In contrast, hydrochlorothiazide increased urinary potassium excretion in three patients from 34 ± 8 mEq/day to 54 ± 5 mEq/day, and serum potassium concentrations fell to normal in all. Three patients, restudied when the serum potassium concentrations were normal, had kaliuretic responses to 9 α fluorohydrocortisone and furosemide. These data demonstrate a reversible defect in urinary potassium excretion following renal transplantation. The impaired response to mineralocorticoids suggests that this defect is related to an abnormality of renal tubular function. The mechanism of correction with thiazides is unknown.

Original languageEnglish (US)
Pages (from-to)357-365
Number of pages9
JournalKidney International
Volume11
Issue number5
StatePublished - 1977
Externally publishedYes

Fingerprint

Hyperkalemia
Kidney Transplantation
Potassium
Furosemide
Fludrocortisone
Mineralocorticoids
Sodium
Aldosterone
Serum
Thiazides
Oliguria
Kidney
Sodium-Restricted Diet
Natriuresis
Acetazolamide
Sodium Bicarbonate
Hydrochlorothiazide
Renin-Angiotensin System
Acidosis
Renal Insufficiency

ASJC Scopus subject areas

  • Nephrology

Cite this

Defronzo, R. A., Goldberg, M., Cooke, C. R., Barker, C., Grossman, R. A., & Agus, Z. S. (1977). Investigations into the mechanisms of hyperkalemia following renal transplantation. Kidney International, 11(5), 357-365.

Investigations into the mechanisms of hyperkalemia following renal transplantation. / Defronzo, Ralph A; Goldberg, M.; Cooke, C. R.; Barker, C.; Grossman, R. A.; Agus, Z. S.

In: Kidney International, Vol. 11, No. 5, 1977, p. 357-365.

Research output: Contribution to journalArticle

Defronzo, RA, Goldberg, M, Cooke, CR, Barker, C, Grossman, RA & Agus, ZS 1977, 'Investigations into the mechanisms of hyperkalemia following renal transplantation', Kidney International, vol. 11, no. 5, pp. 357-365.
Defronzo RA, Goldberg M, Cooke CR, Barker C, Grossman RA, Agus ZS. Investigations into the mechanisms of hyperkalemia following renal transplantation. Kidney International. 1977;11(5):357-365.
Defronzo, Ralph A ; Goldberg, M. ; Cooke, C. R. ; Barker, C. ; Grossman, R. A. ; Agus, Z. S. / Investigations into the mechanisms of hyperkalemia following renal transplantation. In: Kidney International. 1977 ; Vol. 11, No. 5. pp. 357-365.
@article{db2ddd8c515f4e0abebddeec3ac36db3,
title = "Investigations into the mechanisms of hyperkalemia following renal transplantation",
abstract = "Hyperkalemia was observed in 23 of 75 patients in the first three months following renal transplantation. The hyperkalemia was unrelated to rejection, renal failure, oliguria, or acidosis. Six patients (four with hyperkalemia and two with normal serum potassium) were studied to evaluate the role of the renin angiotensin aldosterone system and/or impairment of renal tubular potassium handling in this syndrome. Following equilibration on a normal dietary intake, patients were placed on a low sodium diet and were given furosemide. All patients achieved sodium and potassium balance during both periods, but at the expense of significant hyperkalemia (5.3 to 5.7 mEq/liter) in the four patients with preexisting hyperkalemia. Plasma aldosterone concentration and urinary aldosterone excretion rates in the hyperkalemic patients were 8.4 ± 0.6 ng/dl and 2.8 ± 1.1 μg/day, respectively, on a control diet, and they rose appropriately to 15.4 ± 1.9 ng/dl and 20.3 ± 1.4 μg/day with sodium restriction. Subsequent administration of exogenous mineralocorticoid, 9 α fluorohydrocortisone (Florinef), 1 mg/day, while the sodium intake was high, failed to increase urinary potassium excretion. Neither furosemide nor acetazolamide plus sodium bicarbonate administration produced a consistent increase in potassium excretion despite a significant natriuresis. In contrast, hydrochlorothiazide increased urinary potassium excretion in three patients from 34 ± 8 mEq/day to 54 ± 5 mEq/day, and serum potassium concentrations fell to normal in all. Three patients, restudied when the serum potassium concentrations were normal, had kaliuretic responses to 9 α fluorohydrocortisone and furosemide. These data demonstrate a reversible defect in urinary potassium excretion following renal transplantation. The impaired response to mineralocorticoids suggests that this defect is related to an abnormality of renal tubular function. The mechanism of correction with thiazides is unknown.",
author = "Defronzo, {Ralph A} and M. Goldberg and Cooke, {C. R.} and C. Barker and Grossman, {R. A.} and Agus, {Z. S.}",
year = "1977",
language = "English (US)",
volume = "11",
pages = "357--365",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Investigations into the mechanisms of hyperkalemia following renal transplantation

AU - Defronzo, Ralph A

AU - Goldberg, M.

AU - Cooke, C. R.

AU - Barker, C.

AU - Grossman, R. A.

AU - Agus, Z. S.

PY - 1977

Y1 - 1977

N2 - Hyperkalemia was observed in 23 of 75 patients in the first three months following renal transplantation. The hyperkalemia was unrelated to rejection, renal failure, oliguria, or acidosis. Six patients (four with hyperkalemia and two with normal serum potassium) were studied to evaluate the role of the renin angiotensin aldosterone system and/or impairment of renal tubular potassium handling in this syndrome. Following equilibration on a normal dietary intake, patients were placed on a low sodium diet and were given furosemide. All patients achieved sodium and potassium balance during both periods, but at the expense of significant hyperkalemia (5.3 to 5.7 mEq/liter) in the four patients with preexisting hyperkalemia. Plasma aldosterone concentration and urinary aldosterone excretion rates in the hyperkalemic patients were 8.4 ± 0.6 ng/dl and 2.8 ± 1.1 μg/day, respectively, on a control diet, and they rose appropriately to 15.4 ± 1.9 ng/dl and 20.3 ± 1.4 μg/day with sodium restriction. Subsequent administration of exogenous mineralocorticoid, 9 α fluorohydrocortisone (Florinef), 1 mg/day, while the sodium intake was high, failed to increase urinary potassium excretion. Neither furosemide nor acetazolamide plus sodium bicarbonate administration produced a consistent increase in potassium excretion despite a significant natriuresis. In contrast, hydrochlorothiazide increased urinary potassium excretion in three patients from 34 ± 8 mEq/day to 54 ± 5 mEq/day, and serum potassium concentrations fell to normal in all. Three patients, restudied when the serum potassium concentrations were normal, had kaliuretic responses to 9 α fluorohydrocortisone and furosemide. These data demonstrate a reversible defect in urinary potassium excretion following renal transplantation. The impaired response to mineralocorticoids suggests that this defect is related to an abnormality of renal tubular function. The mechanism of correction with thiazides is unknown.

AB - Hyperkalemia was observed in 23 of 75 patients in the first three months following renal transplantation. The hyperkalemia was unrelated to rejection, renal failure, oliguria, or acidosis. Six patients (four with hyperkalemia and two with normal serum potassium) were studied to evaluate the role of the renin angiotensin aldosterone system and/or impairment of renal tubular potassium handling in this syndrome. Following equilibration on a normal dietary intake, patients were placed on a low sodium diet and were given furosemide. All patients achieved sodium and potassium balance during both periods, but at the expense of significant hyperkalemia (5.3 to 5.7 mEq/liter) in the four patients with preexisting hyperkalemia. Plasma aldosterone concentration and urinary aldosterone excretion rates in the hyperkalemic patients were 8.4 ± 0.6 ng/dl and 2.8 ± 1.1 μg/day, respectively, on a control diet, and they rose appropriately to 15.4 ± 1.9 ng/dl and 20.3 ± 1.4 μg/day with sodium restriction. Subsequent administration of exogenous mineralocorticoid, 9 α fluorohydrocortisone (Florinef), 1 mg/day, while the sodium intake was high, failed to increase urinary potassium excretion. Neither furosemide nor acetazolamide plus sodium bicarbonate administration produced a consistent increase in potassium excretion despite a significant natriuresis. In contrast, hydrochlorothiazide increased urinary potassium excretion in three patients from 34 ± 8 mEq/day to 54 ± 5 mEq/day, and serum potassium concentrations fell to normal in all. Three patients, restudied when the serum potassium concentrations were normal, had kaliuretic responses to 9 α fluorohydrocortisone and furosemide. These data demonstrate a reversible defect in urinary potassium excretion following renal transplantation. The impaired response to mineralocorticoids suggests that this defect is related to an abnormality of renal tubular function. The mechanism of correction with thiazides is unknown.

UR - http://www.scopus.com/inward/record.url?scp=0017685325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017685325&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 357

EP - 365

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -